• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention provides a 1,8-naphthyridine compound of the formula wherein R is hydrogen, methyl, ethyl or propyl, and a nontoxic pharmaceutically acceptable salt thereof, -an antibacterial agent comprising said 1,8-naphtyridine compound -and a process for prearing a 1,8-naphtyridine compound of the above formula which comprises (A) reacting a compound oftheformula: with a compound of the formula or (B) decomposing a compound of the formula or (C) treating a compound of the formula with an acid or base, and/or reducrively cleaving it.
    公开号:SU1060112A3
    申请号:SU802986385
    申请日:1980-09-26
    公开日:1983-12-07
    发明作者:Мацумото Юн-Ити；Такасе Есиюки；Нисимура Есиро
    申请人:Дайниппон Фармасьютикал Ко.,Лтд (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to the preparation of the HOBbix derivatives of the naphthyridine series, which can be used in medicine.
    The literature describes the resulting amines by the alkylation reaction L,
    The purpose of the invention is to develop, on the basis of a known method, a method of obtaining new compounds that possess pharmacological and valuable properties. :,,. „. .
    The goal is achieved by the fact that according to the method for producing 1,8-naphthyridine-3-carboxylic acid derivatives of the general formula
    ABOUT
    where R is hydrogen, methyl, ethyl or
    propyl, compound of general formula
      . , -about;.
    I
    ... -. General Staff:
    where Y is a halogen, a lower alkoxy, akylthio group, a hydroxy sulfonyl, an alkylsulfonyl, an alkylsulfonylxy or an arylsulfonyloxy group; - R ;, - hydrogen hydrogen or lower alkyl, is reacted with 3-aminopyrrolidine of the general formula
    -R L / H
    where r
    imgett these values;
    R2; - hydrogen OR: a protecting group for the amino group, and the desired product is isolated or, when R is lower alkyl and / or. R, 2 is an amino protecting group, treated with an acid or base and / or reduced to cleavage.
    The resulting compounds can be converted into salts by the action of acids or bases. Various inorganic and organic acids can be used as the acid, in particular the acceptable acids are hydrochloric, acetic, lactic, succinic, lactobionic acids and methanesulfonic acid. Any inorganic and organic bases which can form salts with carboxyl groups can be used as bases. for example, hydrates of oxides, in particular hydrates of oxides of sodium or potassium, and
    metal carbonates, in particular sodium and potassium carbonates.
    Preferred salts of the compounds according to the invention are hydrochlorides and methanesulfonates.
    5, depending on the process conditions, naphthyridine compounds may form in the form of hydrates.
    Examples of protecting groups R2, which can be removed by treatment with acid or bases, are acyl groups, in particular formyl, acetyl, trifluoroazethyl, benzyl Loxycarbonyl, tert-butoxycarbonyl,
    5 d-methoxybenzyloxycarbonyl, vinyloxycarbonyl, ethoxycarbonyl and / J 4 (p-toluenesulfonyl) ethoxycarbonyl, lower trialkylsilyl groups, particularly the trimethylsilyl and dimethylsilyl tret.butil0, galoidetoksikarbonilnye groups, in particular / i, |, and; 5-trichloroethoxycarbonyl, p , iodoethoxycarbonyl, o-nitrophenylsulphenyl, trtythyl, tetrahydropyranyl, and diphenyl5 phosphinyl.
    Examples of protecting groups Rj / which can be easily udgshcheny by reductive cleavage are the arylsulfonyl groups. n-toluenesulfonyl, methyl
    0 groups substituted by a phenyl or benzyloxy group, in particular benzyl, trityl and bbnzyloxymethyl, arylmethylcarbonyl groups, in particular benzyloxycarbonyl or p-methoxybenzyloxycarbonyl.
    The treatment with an acid or base is carried out in the presence or absence of ;, (s, which depends on the α-type of protecting group for the amine. For example,
    0 this process is usually carried out in the presence of water, when the Rj acyl group, in particular formyl, acetyl, trifluoroacetyl, benzyloxycarbonyl, tert-butoxycarbonyl, p-methoxy5 benzyloxycarbonyl, vinyloxycarbonyl or ethoxycarbonyl .; the lower trialkylsilyl group, in particular trimethylsilyl or tert.butyldimethylsilyl, trityl, tetrahydropyraL NIL ..
    Water is usually used as a solvent, but depending on the properties of the compound formed, it is also possible to use such
    5 solvents like ethanol, dioxane, ethylene glycol - dimethyl ether, benzene or acetic acid together with water. Typically, the reaction temperature is approximately O-ISO C,
    0 preferably about 30-100 seconds.
    In that case, when R2- / 5- (1-dimelylsulfonyl) -ethoxycarbonyl or 0-nitrophenylsulfenyl, /, /}, p-trichloroxytoxycarbonyl, / 5 -iodozotoxycarbo5 NILE or diphenylphosphinyl, treatment
    acid or base is usually carried out in the absence of water. This reaction can, for example, be carried out by introducing the compound in which (n tolsulfonyl) -ethoxycarbonyl, in contact with an alkali metal alkoxide, in particular sodium methoxide or sodium ethoxide, in alcohol, in particular in methanol or ethanol, at 0-80 ° WITH. In the case when R2 is o-nitrophenylsulphenyl, this treatment is carried out by contacting this compound with glacial; acetic acid at. In the same case, when R2 is R. / L / P-trichloroethoxycarbonyl or (i-iodoethoxycarbonyl), the reaction is also carried out by treating said compound with zinc dust in acetic acid or methanol at 0-80 ° C. In the case when R is lower alkyl, it is also possible to convert the radical R to a hydrogen atom during treatment with an acid or base by adding water to the reaction system and holding it at a temperature of about 30-100 ° C.
    Reductive cleavage is carried out as follows, although the reaction conditions are different in different cases and depend on the type of protecting group Rj. For example, when R is a methyl group substituted by a phenyl or benzyloxy group (e.g. benzyl, trityl or benzyloxymethyl): or an arylmethoxycarbonyl group, in particular benzyloxycarbonyl or P-methoxybenzyloxycarbonyl, the reduction reaction is carried out by treating the compound with a stream of hydrogen in an inert solvent. the presence of a catalyst, in particular platinum, palladium, Rene nickel or the like
    The process of catalytic hydrogenolysis is carried out at room temperature, but it can be carried out at elevated temperature, reaching 60 ° C. Suitable solvents for this reaction are ethylene glycol, dioxane, dimethylformamide, ethanol and acetic acid. .
    The proposed compounds have extremely strong antibacterial. general effect and low toxicity. Thus, these compounds can be used as medicaments for treating or preventing bacterial infections of warming blocs, including humans.
    The daily dose of a compound or its salt according to the invention, when administered to a human body, should be adjusted depending on the age, body weight and condition of the particular patient to be treated, the route of administration, frequency of administration, etc. It is usually 1 , 6-120 mg / kg of body weight per day, preferably 385 mg / kg of body weight per day, for adults and children (the most frequently daily dosage for adults is 0.1-7 g, preferably 0.2-5 g).
    The compounds may be used as medicaments, for example, in the form of pharmaceutical preparations containing these compounds in admixture with organic or inorganic pharmaceutically acceptable solid or liquid additives suitable for oral or topical administration.
    Pharmaceutically acceptable additives are substances that do not react with the proposed compounds, such as water, gelatin, lactose, starch, β-cellulose (preferably microcrystalline cellulose), carboxymethylcellulose, methylcellulose, sorbitol, magnesium stearate, talc, vegetable oils, benzyl alcohol, gums, propylene glycols, methyl para-aminobenzoic acid and other well-known additives for medications. Pharmaceutical preparations can be prepared in the form of powder, granules, tablets, ointments, suppositories, creams, capsules, etc. They can be sterilized and / or contain excipients,. in particular preservatives, stabilizing or wetting agents. Moreover, such preparations may include other therapeutically valuable substances depending on the purpose of the medication.
    Pharmaceutical preparations, such as tablets and capsules, may contain about 50-700 mg, typically 100-500 mg of the proposed compound per tablet or capsule. These quantities are not necessary, they can be changed depending on whether you need to enter the required amount immediately or in separate portions.
    Example 1. A mixture containing 2.7 g of 7-chloro-1-ethyl-6-fluoro-1,4-dihydro-4-OKCo-1, 8-naphthyridine-3-carboxylic acid, 1.01 g of triethylamine, 2 56 g of 3-ethylaminopyrrolidine and 100 ml of acetonitrile are refluxed for 2 hours. The mixture is then concentrated to dryness under reduced pressure. The residue is mixed with water, neutralized with acetic acid and cooled. The residue is collected, washed successively with water and ethanol and dried to give 3.2 g of 7- (3-acetylamino-1-pyrrolidinyl) -1-methyl-6-fluoro-1,4-dihydro-4-OXO-1, 8- naphthyridine-3-carboxylic acid with so pl. 283-284 ° С (after preliminary recrystallising from a mixture of dimethyl formamide with ethanol). a) A mixture of 1.81 g of 7- (3-acetylamino-1-PIRRHSHIDINIL) -1-ETHYL-6-FTOR-1,4-LI1: idro-4-oxo-1, 8-naphthyridine-3-carboxylic acid in 20 ml of 20% hydrochloric acid is refluxed with stirring for 3 hours. This mixture was concentrated by evaporation to dryness under reduced pressure, and then ethanol was added to the residue. After cooling this mixture, the resulting solid material is collected and recrystallized from ethanol / water, resulting in 1.64 g of 7- (3-amino-1-pyrrolidinyl) -1-ethyl-6-fluoro-1, 4-DIHYDRO -4-OXO-1,8-naphthyridine-3-carboxylic acid in the form of its hydrochloride (compound I) with m.p. 285 290 ° С (with decomposition). c) A solution of 0.88 g of 7- (3-acetylamino-1-pyrrylidinyl) -1-ethyl-b-fluoro-1, 4-digi-Dro-4-oxo-1,8-naphthyrid in-3-carboxylic acid in 15 ml of a 10% sodium hydroxide solution are heated under reflux for 5 hours. The solution is then neutralized by adding 20% hydrochloric acid to it, resulting in a precipitate, which is collected, washed successively with water and ethanol, dissolved in 10% acetic acid and the pH adjusted to 7.6-8.0 by adding 10% ammonia water. As a result, 0.70 g of 7- (3-amino-1-pyrrolidinyl) -1-ethyl-6-fluoro -1,7-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid with m. square 259262 ° С (with decomposition). II p im e p. 2. Instead of 3-acetylaminopyrrolidine in this case, 3-benzyloxycarbonylaminopyrrolidine is reacted with 7-chloro-1-ethyl-6-fluoro-1, 4-dihydro-4-oxo-1,8-naphthyridine- 3-carboxylic acid is analogous to Example 1, as a result of which 7- (3-benzyloxycarbonylamino-1-pyrrolidinyl) -1-et 6-6-fluoro-1,5-dihydro-4-OKCo-1, 8- naphthyridine-3-} arbonic acid, which is used in the next step. a) Solution O, 908 g of the compound thus obtained in 10 ml of a 10% solution of sodium hydroxide solution is kept at 70-80 ° C for 1.5 hours with stirring. Then, the reaction mixture is neutralized by adding 10% hydrochloric acid thereto, and the precipitated precipitate is collected, washed successively with water and ethanol, and dried. The result is 0.60 g of 7-Sz-amino-1-pyrrolidi, nyl) -1-ethyl-6.-fluoro-1,4-DIHIDRO-4-Oxo-1, 8-naphthyridine-3-carboxylic acid with m.p. 259-262 ° С (with decomposition) .. b) Suspension 1.36. 7- (3-benzyloxycar (5onyl-amino-1-pyrrolidinyl) -1-ETHIL-6-FTOR-1, 4-dihydro-4 -oxo-1, 8-naphthyridine-3-carboxylic acid in 50 ml of acetic acid is vigorously shaken together with 136 mg of palladium on charcoal in a hydrogen atmosphere. After hydrogen absorption is stopped, the mixture is filtered to remove palladium on charcoal and the filtrate is concentrated by evaporation to dryness under reduced pressure, it is diluted with water and the pH of the solution is adjusted to 8 by adding 10% ammonia solution, as a result of which go get the residue, which is collected and dried to obtain 0.79.7 g of 7- (3-amino-1-pyrrolidinyl) -1-ethyl-6-fluoro-1, 4-dihydro-4-oxo-1,8-naphthyridine- 3-carboxylic acid with a melting point of 259-262s (with decomposition). Example 3. A mixture containing 2.7 g of 7-chloro-1-ethyl-b-fluoro-1,4-dihydro-4-oxo- 1, 8-naphthyridine-3-carboxylic acid, 1.01 g of triethylamine, 1.72 g of 3-aminopyrrolidine and 100 ml of acetonitrile, are refluxed for 1.5 hours. After cooling the mixture, the precipitated precipitate is collected and suspended in 20 ml of water. The pH of this suspension is adjusted to 7.5-8.0 by adding acetic acid thereto. The precipitate is collected, washed with water and dried to obtain 2.85 g of 7- (3-amino-1-pyrrolidinyl) -1-ethyl-6-fluoro-1, 4-DIGIDRO-4-OXO-1,8-naphthyridine-3 -carboxylic acid, so pl. which 259-262 ° C (with decomposition). PRI me R 4. A mixture containing 5.41 g of 7-chloro-1-ethyl-6-fluoro-1., 4-dihydro-4-oKco-1, 8-naphthyridine-3-carboxylic acid, 4 / 26 g of 3- (L-acetylmethylamino) -pyrrolidine, 6.06 g of triethylamine and 100 ml of ethanol, are refluxed with stirring for 2 hours. The reaction mixture is concentrated by evaporation to dryness under reduced pressure. 70% are added to the residue ml of VOD1L and 15 ml of acetic acid. After cooling the mixture, the residue is collected, washed with water and recrystallized from dimethylformamide. 7.4 g of 7-t. 3- (N-acetylmethylamino) -l-pyrrolidinyl-1-ethyl-6-fluoropl, 4-dicidro-4-occo-i, 8-naphthyridine-3-carboxylic acid are obtained. acid s.pl. 287-289 ° C. 3.0 g of the N-acetylmethylamine compound thus obtained are dissolved in 30 ml of a 10% sodium hydroxide solution. This solution is boiled under reflux for 6 hours and then the pI is adjusted to 7-8 by adding acetic acid to the solution. The precipitate is collected, washed with water and dissolved in 1N. sodium hydroxide solution. Then the solution is brought back to 7-8 by adding c. it with acetic acid to obtain a precipitate, which is collected, washed with water and dried. Thus, 1.92 g of 1-ETHYL-6-FTOR-1,4-dihydro-7- (3-methyl. Amino-1-pyrrolidinyl) -4-oxo-1,8-naphthyridine-3-carboxylic acid are obtained. from m.p. 242-242,5 ° C. 1.0 g of the methylamino compound of the compound thus obtained is dissolved in 5 ml of 1N hydrochloric acid. To this hot solution, 45 ml of ethanol is added and the mixture is cooled. The precipitated precipitate is collected and dried, resulting in a yield of 0.97 g of 1-ethyl-6-fluoro-1,4-dihydro-7- (3-methyl-amino-1-pyr-pyridinyl) -4-oco-1, 8-naphthyridine- 3-carboxylic acid in the form of its hydrochloride (compound 2) with so pl. approximately 270 C (with decomposition). I In this case, 3- (N-acetyl-n-propylamino) -pyrrolidine is reacted with 7-chloro-1-ethyl-b-fluoro-1,4-dihydro-4-OKCo-1, 8-naphthyridine-3 -carboxylic acid in the same way as described above, as a result of which 7-C- (N-acetyl-n-propylamino) -1-pyrrhea is obtained; gadinyl -1-ethyl-b-fluoro-1, 4-DIHYDRO- 4-OXO-1, P naphthyridine-3-carboxylic acid. The last hydrolysis of this compound with hydrochloric acid gives 1 ext-1-6-fluoro-1,4-dihydro-4-pxo-7- 3- (M-propylamino-1) -pyrrolidinyl-, 8-naphthyridine-3-cara. in the form of its hydrochloride with so pl. approximately 270 ° C (with decomposition). Example 5. A mixture containing 2.99 g of ethyl-7-chloro-1-ethyl-6-fluoro-1f4-dihydro-4-OKCo-1, 8-naphthyridine-3-car bauxyl, 2.13 g of 3- ( N-acetylmethylamino) -pyrrolidine, 1/52 g of triethylamine and 30 ml of chloroform were refluxed with stirring for 4 hours. After cooling, 20 ml of 5% hydrochloric acid was added. The chloroform layer was separated, the solvent was evaporated. 20 ml of acetonitride is added to the residue and the mixture is cooled. The resulting precipitate is collected and recrystallized from acetonitrile, resulting in 3.51 g of ethyl 7-C- (M-acetylmethyls1Mino) -1-pyrrolidinyl -1-ETSH1-6-Fluoro-1,4-DIGIDRO-4-OXO- 1, E-naphthyridine-3-carboxylate with so pl. 212-213 ° C. A solution of 2.02 g of the compound thus obtained in 20 ml of a 10% sodium hydroxide solution is heated to reflux with stirring for 6 hours. The mixture is processed in the same way as described in Example 4, resulting in 1 22 g of 1-ethyl-6-fluoro-1,4-dihydro-7- (3-methylamino-1-pyrralidinyl) -4-oxo-1,8-naphthyridine-3-carboxylic acid with m.p. 242-242 ,. Example A mixture containing g of ethyl-1-methyl-7-ethyl-su lofonyl-6-fluoro-1, 4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate, 2.13 g 3 (N-acetylmethylamino ) -pyrrolidine and 70 ml of acetoiitrile, is heated under reflux for 3 hours. After cooling the mixture, the precipitate is collected and extracted from acetonitrile, resulting in 1.58 g of ethyl-7- (S-acetylmethyl) Eno) -1-pyrrolidinyl -1-ethyl-6-fluoro-1, 4-dihydro-4-OKco-1, 8-naphthyridine-3-carboxylate with m.p. 212-213 ° C. The compound thus obtained is hydrolyzed by treating it with hydrochloric acid in the same way as described in Example 1a. The result is 1-ethyl-6-fluoro-1, 4-DIHIDRO-7- (3-methylamino-1-pyrrolidinyl) -4-OXO-1,8-naphthyridine-3-carboxylic acid hydrochloride (compound 2) with t .pl. approximately 270 ° C (with decomposition), Example 7. A mixture containing ethyl 1-ETHYL-7-ETHYLTIO-6-fluoro-1, 4-DIGYDRO-4-OXO-1,8-naphthyridine-3-carboxylic acid ( 3.24 g), 3-ethoxycarbonylaminopyrrolidine (4.74 g) and acetonitrile (100 ml), is stirred at reflux with stirring for 5 hours. The reaction mixture is concentrated to dryness under reduced pressure. Ethanol (30 ml) was added to the residue and the mixture was cooled. The precipitate is collected. A suspension of the compound thus obtained in 10% sodium hydroxide (40 ml) with stirring is refluxed for 5 hours. The solution is cooled and the pH is adjusted to 7-8 with 10% acetic acid. The precipitate is collected, washed with water and dried. 1.86 g of 7- (3-amino -1-pyrrolidinyl) -1-ethyl-6-fluoro-1,4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid are obtained, m.p. 259-262 ° С (with decomposition). Example 8. A mixture containing 7-ethyl lsulfonyl-1-ethyl-b-fluoro-1, 4-dihydro-4-oxy-1,8-naphthyridine-3-carboxylic acid ethyl ester (3.40 g), 3-trifluoroacetylaminopyrrolidine (5.46 g) and acetonitrile (150 ml, heated under reflux for 1 hour. The reaction mixture
    权利要求:
    Claims (1)
    [1]
    The method of obtaining derivatives
    1.8- naphthyridine-3-carboxylic acid
    general formula 0 ΒΪΗ Ί -λ Γ ΥΊ
    where R is hydrogen, methyl, ethyl or propyl, or salts thereof, wherein wherein Y is halogen, lower alkoxy, alkylthio group, alkylsulfinyl, alkylsulfonyl, alkylsulfonyloxy or arylsulfonyloxy group,
    - hydrogen or lower alkyl is reacted with 3-aminopyrrolidine of the general formula wherein R has the indicated meanings;
    Rg is hydrogen or a protective group for the amino group, and the target product is isolated in the free form or in the form of a salt, or, when R p is lower alkyl and / or R 2 is a protective group for the amino group, it is treated with acid or base and / or subjected to reductive cleavage .
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1060112A3|1983-12-07|Process for preparing derivatives of 1,8-naphthyridine-3-carboxylis asid or their salts
    EP0009425B1|1982-01-27|Novel naphtyridine derivatives and pharmaceutical compositions containing them
    EP0535529B1|1997-07-23|Indole derivatives and anti-ulcer compositions
    KR870000441B1|1987-03-10|Process for preparing 7- amino 1- cyclopropyl -4- oxo -1,4 - dihydro - naphthridine -3- carboxylic acids
    US5665730A|1997-09-09|Pharmaceutically useful imidazopyridines
    KR910006806B1|1991-09-02|Process for preparing quinaline derivatives
    HU198198B|1989-08-28|Process for production of new derivatives of quinoline and medical preparatives containing them as active substance
    KR880002353B1|1988-10-29|Quinoline compounds and process for the preparation thereof
    RU2139288C1|1999-10-10|Imidazo[1,2-a]pyridine alkoxyalkylcarbamates and drug based on said
    EP0208210A1|1987-01-14|Pyridonecarboxylic acid derivatives and process for their preparation
    HU219581B|2001-05-28|Novel pyridone carboxylic acid derivatives, processes for their production, pharmaceutical compositions containing them and intermediates
    SU1037841A3|1983-08-23|Process for preparing derivatives of 1,8-naphthyridine or their pharmaceutically acceptable salts
    EP0429304A2|1991-05-29|Pyridone-carboxylic acid derivatives and their use as veterinary medicines
    EP0812838B1|2002-05-02|Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor
    AU700737B2|1999-01-14|Benzylimidazopyridines
    KR830000337B1|1983-03-04|Process for preparing naphthyridine derivatives
    EP0339406A1|1989-11-02|Quinoline-3-carboxylic acid derivatives, process for preparing the same, and composition exhibiting excellent antibacterial effect containing the same
    JPH0848629A|1996-02-20|Pyridonecarboxylic acid derivative and anti-pylori agent with the same as active ingredient
    KR830000336B1|1983-03-04|Process for preparing naphthyridine derivatives
    KR830000335B1|1983-03-04|Process for preparing naphthyridine derivatives
    KR830000325B1|1983-03-04|Process for preparing naphthyridine derivatives
    EP0221541A2|1987-05-13|Quinolonecarboxylic acid derivatives and their preparation
    JPH0720941B2|1995-03-08|Novel quinolone derivative, its ester and its salt
    EP0794184A1|1997-09-10|6-methoxy-1h-benzotriazole-5-carboxamide derivatives, process for producing the same, and medicinal composition containing the same
    JP2989865B2|1999-12-13|Pyrroloquinoline derivatives, esters and salts thereof
    同族专利:
    公开号 | 公开日
    CA1147731A|1983-06-07|
    AU6257080A|1981-04-09|
    HU183218B|1984-04-28|
    ES8107217A1|1981-10-01|
    EP0027752A1|1981-04-29|
    JPS5649382A|1981-05-02|
    DK408580A|1981-03-29|
    JPS6113717B2|1986-04-15|
    FI70216B|1986-02-28|
    EP0027752B1|1983-12-21|
    US4341784A|1982-07-27|
    FI803042A|1981-03-29|
    PL226951A1|1981-10-16|
    PH15907A|1983-04-15|
    DK155048B|1989-01-30|
    CS215139B2|1982-07-30|
    FI70216C|1986-09-15|
    AR226320A1|1982-06-30|
    DE3065949D1|1984-01-26|
    AU534288B2|1984-01-19|
    DK155048C|1989-06-26|
    ZA806007B|1981-10-28|
    PL127762B1|1983-11-30|
    YU236480A|1983-02-28|
    DD155990A5|1982-07-21|
    YU42983B|1989-02-28|
    ES495376A0|1981-10-01|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3149104A|1961-01-03|1964-09-15|Sterling Drug Inc|4-hydroxy-7-styryl-1, 8-naphthyridine-3-carboxylic acids and esters|
    US3673193A|1970-05-11|1972-06-27|Sterling Drug Inc|4-oxo-1,8-naphthyridine-3-carboxylates and derivatives thereof|
    US3786043A|1972-06-19|1974-01-15|Sterling Drug Inc|7-methyl-4-chloro -1,8-naphthyridine-3-carboxylates|
    US4024255A|1973-04-05|1977-05-17|Allen & Hanburys Limited|Tetrazole containing naphthyridine-3-carboxamides|
    JPS5637232B2|1973-04-17|1981-08-29|
    JPS587626B2|1974-02-13|1983-02-10|Dainippon Pharmaceutical Co|
    HU173573B|1975-02-18|1979-06-28|Chinoin Gyogyszer Es Vegyeszet|Process for producing new 1,8-naphtridine derivatives|
    DE2607012A1|1976-02-18|1977-08-25|Schering Ag|-Substd. -naphthyridine--carboxylic acid derivs. - prepd. by -alkylating -unsubstituted cpds., the prods. being useful as urinary tract antibacterials|
    IL51092D0|1976-12-10|1977-02-28|Abic Ltd|Naphthyridine derivatives and their preparation|
    JPS543095A|1977-06-09|1979-01-11|Daito Koeki|Preparation of 188naphthyridine derivative|
    SE444566B|1977-09-20|1986-04-21|Bellon Labor Sa Roger|7-DIALKYLAMINE-6-HALOGEN-4-OXO-1,4-DIHYDROQINOLINE-3-CARBOXYLIC ACID, PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL PREPARATION OF THEREOF|
    AR223983A1|1978-08-25|1981-10-15|Dainippon Pharmaceutical Co|A PROCEDURE FOR PREPARING 6-HALOGEN-4-OXO-7- -1,8-NAFTIRIDIN-3-CARBOXYLIC ACID DERIVATIVES|
    JP5403095B2|2011-12-20|2014-01-29|ダイキン工業株式会社|Refrigeration equipment|US4382937A|1981-02-27|1983-05-10|Dainippon Pharmaceutical Co., Ltd.|Naphthyridine derivatives and their use as anti-bacterials|
    JPS57146775A|1981-03-06|1982-09-10|Dainippon Pharmaceut Co Ltd|1,8-naphthyridine derivative and its salt|
    JPH0372627B2|1982-07-30|1991-11-19|Dainippon Pharmaceutical Co|
    US5281612A|1982-09-09|1994-01-25|Warner-Lambert Company|Naphthyridine antibacterial agents|
    IE55898B1|1982-09-09|1991-02-14|Warner Lambert Co|Antibacterial agents|
    US4777175A|1982-09-09|1988-10-11|Warner-Lambert Company|Antibacterial agents|
    FR2559484B2|1983-07-06|1986-09-26|Provesan Sa|NEW DERIVATIVE 7-OF 1-ETHYL-1,4-DIHYDRO-4-OXO--3-CARBOXYLIC ACID, ITS PREPARATION AND ITS APPLICATION AS A MEDICAMENT|
    CS274601B2|1983-07-27|1991-09-15|Dainippon Pharmaceutical Co|Method of 1,8-naphthyridine derivative production|
    JPH0430396B2|1983-11-21|1992-05-21|
    NZ210847A|1984-01-26|1988-02-29|Abbott Lab|Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions|
    US4665079A|1984-02-17|1987-05-12|Warner-Lambert Company|Antibacterial agents|
    DE3409922A1|1984-03-17|1985-09-26|Bayer Ag, 5090 Leverkusen|1,7-DIAMINO-1,4-DIHYDRO-4-OXO-3-CHINOLINE CARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN FIGHTING BACTERIAL DISEASES|
    US4571396A|1984-04-16|1986-02-18|Warner-Lambert Company|Antibacterial agents|
    JPH0568477B2|1984-06-06|1993-09-29|Dainippon Pharmaceutical Co|
    US4604401A|1984-07-20|1986-08-05|Warner-Lambert Company|Antibacterial agents III|
    DE3508816A1|1985-01-10|1986-07-10|Bayer Ag, 5090 Leverkusen|6,7-DISUBSTITUTED 1-CYCLOPROPYL-1,4-DIHYDRO-4-OXO-1,8-NAPHTYRIDINE-3-CARBONIC ACIDS|
    US4851535A|1985-01-23|1989-07-25|Toyama Chemical Co., Ltd.|Nicotinic acid derivatives|
    DE3525108A1|1985-06-07|1986-12-11|Bayer Ag, 5090 Leverkusen|ANTIBACTERIAL EFFECT OF CHINOLON CARBON ACID ESTERS|
    US4692454A|1986-02-03|1987-09-08|Warner-Lambert Company|Opthalmic use of quinolone antibiotics|
    US4954507A|1986-10-08|1990-09-04|Bristol-Myers Company|1-tertiary-alkyl-substituted naphthyridine carboxylic acid antibacterial agents|
    ZA877471B|1986-10-08|1988-04-05|Bristol-Myers Company|1-tertiary-alkyl-substituted naphthyridine-and quinoline-carboxylic acid antibacterial agents|
    US4923879A|1987-07-31|1990-05-08|Warner-Lambert Company|1,8-Naphthyridines and their use as antibacterial agents|
    US4962108A|1987-07-31|1990-10-09|Warner-Lambert Company|Antibacterial quinoline compounds|
    US4920120A|1988-01-25|1990-04-24|Warner-Lambert Company|Antibacterial agents|
    US5585491A|1988-01-25|1996-12-17|Otsuka Pharmaceutical Co., Ltd.|Antibacterial agents|
    KR910003630B1|1988-06-17|1991-06-07|한국과학기술원|Benzoyl acetic ester derivatives and there of method|
    US5585264A|1988-07-15|1996-12-17|University Of Saskatchewan|Nucleotide sequences encoding recombinant bovine herpesvirus type-1 GI, GIII and GIV polypeptides|
    US5151267A|1988-07-15|1992-09-29|University Of Saskatchewan|Bovine herpesvirus type 1 polypeptides and vaccines|
    IL91648A|1988-09-22|1997-03-18|Abbott Lab|Amino acid quinoline and naphthyridine derivatives, their preparation and pharmaceutical compositions containing them|
    US5262417A|1988-12-06|1993-11-16|The Upjohn Company|Antibacterial quinolone compounds|
    US5527910A|1992-12-30|1996-06-18|Cheil Foods & Chemicals, Inc.|Pyridone carboxylic acid compounds and their uses for treating infectious diseases caused by bacteria|
    JPH08213881A|1995-02-02|1996-08-20|Fujitsu Ltd|Frequency control circuit|
    US5994365A|1997-02-25|1999-11-30|Diazans Limited|Substituted diazaanthracene compounds having pharmaceutical utility|
    US6387928B1|1997-09-15|2002-05-14|The Procter & Gamble Co.|Antimicrobial quinolones, their compositions and uses|
    CO4970702A1|1997-09-15|2000-11-07|Procter & Gamble|ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND THEIR USES|
    WO2007110836A1|2006-03-28|2007-10-04|The Procter & Gamble Company|A hydride reduction process for preparing quinolone intermediates|
    BRPI0709220A2|2006-03-28|2011-07-12|Procter & Gamble|coupling process for preparation of quinolone intermediates|
    US8039485B2|2006-03-28|2011-10-18|Warner Chilcott Company, Llc|Malate salts, and polymorphs of -7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid|
    AR096135A1|2013-05-02|2015-12-09|Actelion Pharmaceuticals Ltd|DERIVATIVES OF QUINOLONA|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP54126223A|JPS6113717B2|1979-09-28|1979-09-28|
    [返回顶部]